Search results for: biosimilars

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP | May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab

Michele B. Kaufman, PharmD, BCGP | May 24, 2021

As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.

RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett

Zach Wallace, MD, MSc | May 7, 2021

At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.

Neti Pots, Nurse Ambassadors & American Healthcare

Philip Seo, MD, MHS | March 15, 2021

Just YouTube it. As a rheumatologist who sees many patients with granulomatosis with polyangiitis (GPA), I have spent a significant portion of my life talking to people about neti pots. Originally, the neti pot was part of the Ayurvedic tradition. Neti pots were used to flush the sinuses with water, milk and ghee, or to…

FDA Provides 2020 Rheumatology Drug Update

Susan Bernstein | December 17, 2020

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR | December 17, 2020

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

Biologics in Rheumatology: Revolution & Perspectives

Lara C. Pullen, PhD | December 8, 2020

A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.

Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

Michele B. Kaufman, PharmD, BCGP | December 7, 2020

Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR | November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Advancing Rheumatology Care Through State & Local Societies

Chris Adams, MD, FACP, FACR | November 6, 2020

As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.